Biomarkers in clozapine-responding schizophrenia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515338-34-01

Acronym

BICS2019

Enrollment

200

Registered

2024-10-23

Start date

2024-10-10

Completion date

Unknown

Last updated

2025-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Permeability of the blood-brain barrier blood and CSF inflammatory cytokines

Interventions

DRUGCLOZAPINE

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Permeability of the blood-brain barrier blood and CSF inflammatory cytokines	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026